慢性thromboembo TY - T1的炎症lic pulmonary hypertension: accomplice or bystander in altered angiogenesis? JF - European Respiratory Journal JO - Eur Respir J SP - 303 LP - 306 DO - 10.1183/13993003.00962-2015 VL - 46 IS - 2 AU - Hassoun, Paul M. Y1 - 2015/08/01 UR - //www.qdcxjkg.com/content/46/2/303.abstract N2 - Chronic thromboembolic pulmonary hypertension (CTEPH) is not an uncommon cause of pre-capillary pulmonary hypertension (PH). It is thought to be a long-term complication of symptomatic or asymptomatic pulmonary embolism (PE) or venous thromboembolism (VTE) [1–3]. It now appears clear from a retrospective analysis of large European registries [4] and an international prospective registry [5] that CTEPH, as its name indicates, is somehow associated with one or multiple thromboembolic events. However, the reason why a minority of patients (∼0.1–9%) [6, 7] who suffer an initial VTE or PE eventually develop CTEPH while the vast majority manage to resolve their clot and resume normal life remains an enigma. Some clues into the aetiology of the disease are provided by the identification of predisposing factors found in epidemiological studies [4], such as infection (osteomyelitis) and malignancy, indwelling catheters or ventriculo-atrial shunts, splenectomy, chronic inflammatory conditions (e.g. inflammatory bowel disease), and genetic predisposition involving the coagulation system [4, 6].Evidence for the role of inflammation in the pathogenesis of PAH: a new study demonstrates inflammation in CTEPH http://ow.ly/OxixF ER -